NSCLC,HMGB1IFN-γPD-L1

Shumin Wang1, Feng Li1, Liubo Zhang1

  • 1Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.

概括

高流动性组蛋白B1 (HMGB1) 抑制非小细胞肺癌中的PD-L1表达,增强T细胞抗瘤活性. 在肺癌中,HMGB1作为嵌合式抗原受体T细胞治疗的预后指标.